APÊNDICE

**Supplementary Table 1 – Demographic comparison between the prospective and retrospective cohorts**

| | HIPTCN patients n (%) or mean (SD) | Retrospective patients n (%) | Total patients n (%) | p-value* |
|---|---|---|---|---|
| **Total** | 178 (46.4) | 206 (53.6) | 384 | |
| **Gender** | | | | 0.593 |
| Females | 98 (55.1) | 119 (57.8) | 217 (56.5) | |
| **Age†** | 80.95 (9.1) | 81.77 (9.0) | 81.39 (9.1) | 0.880‡ |
| **Type of head trauma** | | | | **0.008** |
| _Low energy_ | _166 (93.3)_ | _203 (98.5)_ | _369 (96.1)_ | |
| Fall own height | 139 (78.1) | - | | |
| Fall bed | 14 (7.9) | - | | |
| Fall stairs | 9 (5.1) | - | | |
| Aggression | 4 (2.2) | - | | |
| _High energy_ | _12 (6.7)_ | _3 (1.5)_ | _15 (3.9)_ | |
| Motor-vehicle accident | 5 (2.8) | 2 (1.0) | | |
| Run over by vehicle | 3 (1.7) | 1 (0.5) | | |
| Fall from height > 3 m | 4 (2.2) | - | | |
| **Type of hypocoagulation** | | | | **<0.0001** |
| Anti-vitamin K | 52 (29.2) | 127 (62.0) | 179 (46.7) | |
| NOAC | 124 (69.7) | 78 (38.0) | 202 (52.7) | |
| Heparins | 2 (1.1) | 0 (0.0) | 2 (0.5) | |
| **Concomitant antiaggregation** | | | | 0.423 |
| Yes | 9 (5.1) | 7 (3.4) | 16 (4.2) | |
| No | 169 (94.9) | 198 (96.6) | 367 (95.8) | |
| _Missing data_ | | _1_ | _1_ | |
| **Concomitant hemorrhagic dyscrasia** | 1 (0.6) | 1 (0.5) | 2 (0.5) | 1.000§ |
| **NTP 1999 risk factors** | | | | |
| Alcohol abuse | 0 | 8 (3.9) | 8 (2.1) | **0.008§** |
| Drug abuse | 0 | 0 | 0 | - |
| Previous neurosurgery | 5 (2.8) | 0 | 5 (1.3) | **0.021§** |
| Epilepsy | 3 (1.7) | 0 | 3 (0.8) | 0.099§ |
| **Admission GCS** | | | | 0.274 |
| 15 | 141 (79.2) | 173 (84.8) | 314 (82.2) | |
| 14 | 36 (20.2) | 29 (14.2) | 65 (17.0) | |
| 13 | 1 (0.6) | 2 (1.0) | 3 (0.8) | |
| _Missing data_ | | _2_ | _2_ | |
| **Admission symptoms** | | | | |
| Headache (n=176) | 30 (17.0) | - | | - |
| Loss of consciousness (n=383) ‖ | 23 (13.0) | 10 (4.9) | 33 (8.6) | **0.005** |
| Amnesia (n=382) ‖ | 23 (13.1) | 12 (5.8) | 35 (9.2) | **0.014** |
| Vomit (n=177) | 7 (4.0) | - | | - |
| Focal deficit | 9 (5.1) | 0 | 9 (2.3) | **0,001§** |
| Usual neurological status | 173 (97.2) | 198 (96.1) | 371 (96.6) | 0.562 |
| **Patients with surveillance CT** | 177 (99.4) | 186 (90.3) | 363 (94.5) | **<0.0001** |
| **Timing for surveillance CT** | | | | **0.002** |
| <12 h | 0 | 2 (1.1) | 2 (0.6) | |
| 12-24 h | 79 (44.6) | 52 (28.1) | 131 (36.2) | |
| >24 h | 98 (55.4) | 131 (70.8) | 229 (63.3) | |
| **Worsening GCS¶** | 4 (2.2) | - | | - |
| **New neurologic deficit** | 2 (1.1) | 0 | 2 (0.5) | 0.214§ |

_* - p-values calculated using the Chi-square test, unless otherwise specified; † - Age is reported as mean (SD), in years. ‡ - p-value calculated using an unpaired two-tailed t-student test; § - p-value was calculated using the Fisher Exact test; ‖- missing data on prospective cohort; ¶ - Post-surveillance GCS was only evaluated in the prospective cohort. GCS – Glasgow Coma Scale; NOAC – novel oral anticoagulant; NTP – National traumatic brain injury protocol; SD – standard deviation._

**Supplementary Table 2 – Risk analysis**

| Variables* | Delayed intracranial hemorrhage n (%) | Neurosurgical hospitalization n (%) | Complications n (%) | Complication hospitalization n (%) |
|---|---|---|---|---|
| **Gender** | | | | |
| Female | 3 (3.1) | 3 (3.1) | 3 (3.1) | 0 (0.0) |
| Male | 1 (1.3) | 0 (0.0) | 4 (5.0) | 2 (2.5) |
| *p-value* | *0.629* | *0.253* | *0.702* | *0.201* |
| **Age** | | | | |
| ≤ 65 years | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 66-80 years | 3 (4.3) | 2 (2.9) | 3 (4.3) | 1 (1.4) |
| > 80 years | 1 (1.0) | 1 (1.0) | 4 (4.0) | 1 (1.0) |
| *p-value†* | *0.323* | *0.608* | *0.856* | *0.926* |
| **Type of head trauma** | | | | |
| Low energy | 4 (2.4) | 3 (1.8) | 6 (3.6) | 2 (1.2) |
| High energy | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
| *p-value* | *1.000* | *1.000* | *0.392* | *1.000* |
| **Type of anticoagulation** | | | | |
| Anti-K | 2 (3.9) | 2 (3.8) | 3 (5.8) | 1 (1.9) |
| NOAC | 2 (1.6) | 1 (0.8) | 4 (3.2) | 1 (0.8) |
| Heparins | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| *p-value†* | *0.632* | *0.354* | *0.701* | *0.805* |
| **Concomitant antiaggregation** | | | | |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 4 (2.4) | 3 (1.8) | 7 (4.1) | 2 (1.2) |
| *p-value* | *1.000* | *1.000* | *1.000* | *1.000* |
| **Concomitant dyscrasia** | | | | |
| Yes | 1 (100) | 1 (100) | 0 (0.0) | 0 (0.0) |
| No | 3 (1.7) | 2 (1.1) | 7 (4.0) | 2 (1.1) |
| *p-value* | ***0.023*** | ***0.017*** | *1.000* | *1.000* |
| **NTP 1999 risk factors** | | | | |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 4 (2.3) | 3 (1.7) | 7 (4.1) | 2 (1.2) |
| *p-value* | *1.000* | *1.000* | *1.000* | *1.000* |
| **Admission GCS** | | | | |
| 15 | 3 (2.1) | 2 (1.4) | 4 (2.8) | 1 (0.7) |
| 14 | 1 (2.8) | 1 (2.8) | 3 (8.3) | 1 (2.8) |
| 13 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| *p-value†* | *0.963* | *0.845* | *0.311* | *0.572* |
| **Admission symptoms‡** | | | | |
| Yes | 2 (3.1) | 1 (1.5) | 0 (0.0) | 0 (0.0) |
| No | 2 (1.8) | 2 (1.8) | 6 (5.4) | 1 (0.9) |
| *p-value* | *0.622* | *1.000* | *0.087* | *1.000* |
| **Worsening GCS†** | | | | |
| Yes | 0 (0.0) | 0 (0.0) | 4 (100) | 2 (50.0) |
| No | 4 (2.3) | 3 (1.7) | 3 (1.7) | 0 (0.0) |
| *p-value* | *1.000* | *1.000* | ***<0.0001*** | ***<0.0001*** |
| **New neurologic deficit** | | | | |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 4 (2.3) | 3 (1.7) | 7 (4.0) | 2 (1.1) |
| *p-value* | *1.000* | *1.000* | *1.000* | *1.000* |

*\* - p-values were calculated using Fisher's Exact Test, unless otherwise specified; † - p-value was calculated using the Chi-square test;  ‡ - Symptoms comprise headaches, loss of consciousness, vomits, amnesia and focal deficit. Anti-K – Anti-vitamin K anticoagulants; GCS – Glasgow Coma Scale; PSCT – Post-surveillance CT scan.*